Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein kinase C eta type (PRKCH), also known as PKC-eta, is a calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase belonging to the novel PKC (nPKC) subfamily. It is predominantly expressed in epithelial tissues and the cell nucleus, playing a critical role in regulating cell cycle progression, keratinocyte differentiation, and T-cell-mediated immune responses.\n\nIn oncology, PRKCH exhibits a complex, context-dependent role, acting as an oncogene that promotes cell proliferation and chemoresistance in glioblastoma, breast cancer, and renal cell carcinoma, while also functioning as a tumor suppressor in other settings. Genetic variants of PRKCH, such as the 1425G/A single nucleotide polymorphism, are strongly associated with susceptibility to cerebral infarction and ischemic stroke. Pharmacological targeting of PRKCH is primarily achieved through multi-kinase inhibitors like sotrastaurin and midostaurin, which compete with ATP binding to inhibit its catalytic activity. However, the high structural conservation of the ATP-binding pocket across the PKC family presents significant challenges for achieving isoform selectivity, raising concerns about off-target toxicities and systemic immunosuppression.
Inhibition of the kinase catalytic activity by competing with ATP binding, or activation via phorbol esters/diacylglycerol mimics.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein kinase C eta type (PRKCH).